# Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers

> **NCT02221375** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BHT low
- **DRUG:** BHT medium
- **DRUG:** BHT high
- **DRUG:** BI 54903 XX low
- **DRUG:** BI 54903 XX medium 1
- **DRUG:** BI 54903 XX medium 2
- **DRUG:** BI 54903 XX high
- **DRUG:** Ciclesonide

## Key facts

- **NCT ID:** NCT02221375
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-09
- **Final completion:** —
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221375, "Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02221375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*